Desamparados Roda

3.7k total citations
39 papers, 858 citations indexed

About

Desamparados Roda is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Desamparados Roda has authored 39 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Desamparados Roda's work include Cancer Genomics and Diagnostics (15 papers), Genetic factors in colorectal cancer (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Desamparados Roda is often cited by papers focused on Cancer Genomics and Diagnostics (15 papers), Genetic factors in colorectal cancer (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Desamparados Roda collaborates with scholars based in Spain, United States and United Kingdom. Desamparados Roda's co-authors include Andrés Cervantes, Marisol Huerta, Susana Roselló, Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Juan Miguel Cejalvo, Pasquale Lombardi, Josefa Castillo and Juan Antonio Carbonell‐Asins and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Desamparados Roda

34 papers receiving 848 citations

Peers

Countries citing papers authored by Desamparados Roda

Since Specialization

Citations

This map shows the geographic impact of Desamparados Roda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Desamparados Roda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Desamparados Roda more than expected).

Fields of papers citing papers by Desamparados Roda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Desamparados Roda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Desamparados Roda. The network helps show where Desamparados Roda may publish in the future.

Co-authorship network of co-authors of Desamparados Roda

This figure shows the co-authorship network connecting the top 25 collaborators of Desamparados Roda. A scholar is included among the top collaborators of Desamparados Roda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Desamparados Roda. Desamparados Roda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life 2025 ·Cancer Treatment Reviews ·(unknown), Susana Roselló, Noelia Tarazona, Marisol Huerta, (unknown), Tania Fleitas, Vicente Pla‐Martí, Alberto Puccini, Desamparados Roda, Andrés Cervantes	0
2	Extended tumor area-based stratification score combining tumor budding and stroma identifies a high-risk, immune-depleted group in localized microsatellite-stable colon cancer patients 2025 ·Pathology - Research and Practice ·B. Daniel Lucas, Begoña Heras, Noelia Tarazona, (unknown), Marisol Huerta, D Moro, (unknown), Desamparados Roda, (unknown), Andrés Cervantes, Carolina Martínez‐Ciarpaglini	0
3	Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis 2025 ·Cancer Treatment Reviews ·(unknown), (unknown), (unknown), Francisco Gimeno-Valiente, (unknown), (unknown), (unknown), (unknown), Diego González, (unknown), (unknown), Susana Roselló, Valentina Gambardella, Desamparados Roda, (unknown), Aparna Parikh, Juan Antonio Carbonell‐Asins, Andrés Cervantes, Noelia Tarazona	1
4	58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study 2024 ·European Journal of Cancer ·Antoine Hollebecque, Efrat Dotan, Chih‐Yi Liao, Desamparados Roda, Elisa Fontana, (unknown), (unknown), Do‐Youn Oh, François Ghiringhelli, Irene Moreno, (unknown), Vivek Subbiah, Andreas Varkaris, Mitesh J. Borad, (unknown), (unknown), (unknown), Fabien Ricard, Kuang‐Yu Jen, Alison M. Schram	1
5	Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Desamparados Roda, Jon Zugazagoitia, Elena Garralda, Alexander I. Spira, Anthony B. El-Khoueiry, Hani M. Babiker, Peter Oppelt, (unknown), Shaozhen Xie, (unknown), Jinping Gan, (unknown), (unknown), William D. Hedrich, (unknown), (unknown), Robert H.I. Andtbacka	0
6	A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma 2023 ·British Journal of Cancer ·Juanita Lopez, Julia Lai‐Kwon, R. Molife, Liam Welsh, Nina Tunariu, Desamparados Roda, (unknown), Victoria Lladó, Adrián G. McNicholl, Catalina Ana Rosselló, Richard Taylor, Analía Azaro, Jordi Rodón, Julieann Sludden, Gareth J. Veal, Ruth Plummer, Ander Urruticoechea, (unknown), (unknown), Pablo V. Escribá	10
7	“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction” 2023 ·Journal of Experimental & Clinical Cancer Research ·Federica Papaccio, (unknown), Francisco Gimeno-Valiente, Manuel Cabeza-Segura, Valentina Gambardella, (unknown), Clara Alfaro‐Cervelló, Carolina Martínez‐Ciarpaglini, Pilar Rentero-Garrido, S. Zúñiga, Juan Antonio Carbonell‐Asins, Tania Fleitas, Susana Roselló, Marisol Huerta, Manuel M. Sánchez del Pino, Luís Sabater, Desamparados Roda, Noelia Tarazona, Andrés Cervantes, Josefa Castillo	49
8	Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer 2023 ·ESMO Open ·Francisco Gimeno-Valiente, (unknown), (unknown), Valentina Gambardella, Carolina Martínez‐Ciarpaglini, (unknown), (unknown), (unknown), (unknown), (unknown), Marisol Huerta, David Moro‐Valdezate, Vicente Pla‐Martí, (unknown), Susana Roselló, Desamparados Roda, Andrés Cervantes, Noelia Tarazona	6
9	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer 2022 ·Clinical Cancer Research ·Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Hendrik‐Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah P. Blagden, Alan Anthoney, Barbara Klencke, Mark Kowalski, Udai Banerji	27
10	Short-term outcomes of colorectal cancer surgery in older patients: a novel nomogram predicting postoperative morbi-mortality 2022 ·Langenbeck s Archives of Surgery ·David Moro‐Valdezate, José Martín‐Arévalo, (unknown), Vicente Pla‐Martí, Stephanie García‐Botello, (unknown), (unknown), Noelia Tarazona, Desamparados Roda, (unknown), (unknown)	3
11	1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC) 2020 ·Annals of Oncology ·Janakiraman Subramanian, Vı́ctor Moreno, Joaquim Bosch‐Barrera, Joanna Pikiel, Rebecca Kristeleit, Wei Guo, Hadi Danaee, E. Im, Desamparados Roda	7
12	420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients 2020 ·Annals of Oncology ·Tenna Vesterman Henriksen, N. Tarazona, Thomas Reinert, Juan Antonio Carbonell‐Asins, Desamparados Roda, Marisol Huerta, Susana Roselló, Anders Husted Madsen, (unknown), Kåre Andersson Gotschalck, Shruti Sharma, (unknown), (unknown), Antony Tin, Himanshu Sethi, Bernhard Zimmermann, Alexey Aleshin, Claus L. Andersen, Andrés Cervantes	2
13	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer 2019 ·Annals of Oncology ·N. Tarazona, Francisco Gimeno-Valiente, Valentina Gambardella, S. Zúñiga, Pilar Rentero-Garrido, Marisol Huerta, Susana Roselló, Carolina Martínez‐Ciarpaglini, Juan Antonio Carbonell‐Asins, (unknown), (unknown), G. Bruixola, Tania Fleitas, (unknown), (unknown), D Moro, Josefa Castillo, Alejandro Espí, Desamparados Roda, Andrés Cervantes	190
14	Gene expression changes responsible for lapatinib acquired resistance in HER2 positive gastric cancer cell lines: a microarray analysis 2017 ·Annals of Oncology ·Valentina Gambardella, Josefa Castillo, Francisco Gimeno-Valiente, Noelia Tarazona, Marisol Huerta, Desamparados Roda, Tania Fleitas, Gloría Ribas, Susana Roselló, Eva Serna, Andrés Cervantes	1
15	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt? 2017 ·Lung Cancer ·Marta Capelán, Desamparados Roda, Elena Geuna, Karim Rihawi, (unknown), Stan B. Kaye, Jaishree Bhosle, Udai Banerji, Mary O’Brien, Johann S. de Bono, Sanjay Popat, Timothy A. Yap	2
16	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? 2015 ·Clinical Cancer Research ·Desamparados Roda, Begoña Jiménez, Udai Banerji	20
17	Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials 2015 ·Clinical Cancer Research ·Saeed Rafii, Desamparados Roda, Elena Geuna, Begoña Jiménez, Karim Rihawi, Marta Capelán, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji	28
18	Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials 2015 ·British Journal of Cancer ·Elena Geuna, Desamparados Roda, Saeed Rafii, Begoña Jiménez, Marta Capelán, Karim Rihawi, Filippo Montemurro, Timothy A. Yap, S.B. Kaye, Johann S. de Bono, L. Rhoda Molife, Udai Banerji	27
19	A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). 2015 ·Journal of Clinical Oncology ·Desamparados Roda, Yvette Drew, Analía Azaro, Alan D. Smith, Alastair Greystoke, Elisabet Sicart, Pablo V. Escribá, Xavier Busquets, Victoria Lladó, (unknown), E. Klumper, Jordi Rodón, L Rhoda Molife, Ruth Plummer	1
20	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial 2014 ·Clinical Cancer Research ·Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Braña, Desamparados Roda, Brian B. Haines, Theresa Zhang, Christopher Winter, Sharda Jha, Youyuan Xu, Jason P. Frazier, Richard A. Klinghoffer, (unknown), (unknown), Scot Ebbinghaus, José Baselga	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact